BioXconomy Marks Banner Year of Expansion
This has been a banner year for BioXconomy. Our outlet has grown dramatically since its launch in Fall 2024. In August 2025, the site expanded its coverage as Søren Hough brought the in-depth technical reporting at Tides Global into the new Modalities section. In parallel, Brandy Fidler brought a range of clinical, legal, compliance, and finance journalism to fill Business Strategy. The result is BioXconomy as you see it today: a one-stop shop for the latest stories about biomedical discovery, clinical impact, with Millie Nelson still leading coverage of Partnering and Investment.
Partnering and Investment has had an absolute blast this year, sharing the juiciest details of the latest deals, capital raises, and collaborations with our amazing readers! From the thrill of interviewing Jan van de Winkel, co-founder and CEO of Genmab, just before he received the prestigious Lifetime Achievement Award, to diving into Europe’s silver lining and counting down our top 10 M&A deals of the year – it’s been a whirlwind of excitement, innovation, and unforgettable moments. Here’s to a year that truly sparkled, and we can’t wait to bring you even more in 2026.
Modalities has thrived on deep reporting, longform features, and interviews with industry leaders. Our focus on antibodies, peptides, oligos, cell and gene therapy, and other emerging modalities has provided insights into the cutting edge of medicine. This summer, the team spoke with leading public health experts to reflect on attacks on mRNA technology coming from the US Department of Health and Human Services. An October story explored how GLP-1 peptides may help prevent heart failure through a mechanism independent from weight loss. In November, our journalists covered an exciting antibody-oligo conjugate approach that could facilitate treatment of neurological conditions.
Business Strategy has hit the ground running, delivering a wealth of insights into the critical intersections of clinical operations, compliance, finance, and market access in the pharma industry.
We’ve highlighted some standout stories that have resonated with our readers:
-
Clinical: Sanofi’s groundbreaking Project Artemis is revolutionizing pharmacovigilance by leveraging advanced AI to enhance drug safety monitoring. Read more
-
Access: Claritas Rx is tackling market access challenges head-on with its innovative Access Analytics platform, providing actionable insights to streamline patient access to therapies. Read more
-
Finance: Financial experts have shared key valuation strategies for pre-launch and post-transaction pharma assets, offering invaluable guidance for navigating the complexities of biotech investments. Read more
-
Compliance: The intersection of social media and pharma has been a hot topic, with our feature exploring the risks and rewards of maintaining a necessary online presence in a highly regulated industry. Read more
This year also marked an exciting expansion for Business Strategy with the launch of two new newsletters: Compliance Insider and BioPharma Finance Insider. These newsletters are designed to provide even deeper insights, perspectives, and strategies for professionals navigating these critical functions. We’re thrilled to see the positive reception they’ve received and look forward to growing our reporting in these areas, offering even more value to our readers.
We are so excited to see what’s in store for 2026. We hope you’ll join us on the frontiers of medical innovation.
link
